Literature DB >> 2013111

The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro.

Y Takemura1, H Kobayashi, H Miyachi, K Hayashi, S Sekiguchi, T Ohnuma.   

Abstract

The effect of tumor cell density on the cellular pharmacokinetics of doxorubicin (DXR) and cisplatin (CDDP) was studied using MOLT-3 human acute lymphoblastic leukemia cells. As determined by the MTT assay, the growth-inhibitory effect of DXR was approx. 40 times lower when cell density was increased from 10(6) to 10(8) cells/ml (positive inoculum effect), whereas little or no influence of cell density was observed in CDDP-induced cell-growth inhibition. As measured by high-performance liquid chromatography using a fluorescence detector, the cellular accumulation of DXR showed 6- and 18-fold decreases after 1 h incubation when the cells were concentrated from 10(6) to 10(7) and 10(8) cells/ml, respectively. Only at low cell density (10(6) cells/ml) did the amount of DXR in the cells increase with increasing exposure times of up to 6 h. The DXR concentration in the supernatant that was separated from a cell suspension showing a density of 10(8) cells/ml fell to 20% of that obtained at 10(6) cells/ml. The metabolites of DXR, including Adriamycinol and Adriamycinone, were not detectable in the cell extracts or supernatants at any cell density examined. In contrast, the cellular accumulation of CDDP calculated from the platinum concentration, which was measured with a flameless atomic absorption spectrophotometer, was essentially identical at all cell densities examined; moreover, extension of the exposure period resulted in a linear increase in the amount of CDDP in the cells. CDDP concentrations in the supernatants were equally retained, irrespective of cell densities. These observations indicate that the positive inoculum effect shown in DXR-induced cell-growth inhibition results from the decreased cellular accumulation of the drug at high cell densities. We found no influence for cell density on the cellular accumulation of CDDP that might be relevant to the therapeutic potentiation of this drug at high tumor-cell density.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2013111     DOI: 10.1007/bf00685154

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry.

Authors:  A F LeRoy; M L Wehling; H L Sponseller; W S Friauf; R E Solomon; R L Dedrick; C L Litterst; T E Gram; A M Guarino; D A Becker
Journal:  Biochem Med       Date:  1977-10

2.  Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocytes.

Authors:  J Minowada; T Onuma; G E Moore
Journal:  J Natl Cancer Inst       Date:  1972-09       Impact factor: 13.506

3.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.

Authors:  T Mosmann
Journal:  J Immunol Methods       Date:  1983-12-16       Impact factor: 2.303

4.  Effect of hypoxia and acidosis on the cytotoxicity of four platinum complexes at normal and hyperthermic temperatures.

Authors:  T S Herman; B A Teicher; L S Collins
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

5.  Alterations in cation homeostasis in cultured chick ventricular cells during and after recovery from adenosine triphosphate depletion.

Authors:  H Ishida; O Kohmoto; J H Bridge; W H Barry
Journal:  J Clin Invest       Date:  1988-04       Impact factor: 14.808

6.  Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells.

Authors:  A A Hindenburg; J E Gervasoni; S Krishna; V J Stewart; M Rosado; J Lutzky; K Bhalla; M A Baker; R N Taub
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

7.  Acid pH in tumors and its potential for therapeutic exploitation.

Authors:  I F Tannock; D Rotin
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

8.  Evidence of a specific complex between adriamycin and negatively-charged phospholipids.

Authors:  E Goormaghtigh; P Chatelain; J Caspers; J M Ruysschaert
Journal:  Biochim Biophys Acta       Date:  1980-03-27

9.  Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro.

Authors:  R E Durand
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

10.  Effect of cell density on intracellular adriamycin concentration and cytotoxicity in exponential and plateau phase EMT6 cells.

Authors:  S H Chambers; N M Bleehen; J V Watson
Journal:  Br J Cancer       Date:  1984-03       Impact factor: 7.640

View more
  13 in total

1.  A mathematical model for comparison of bolus injection, continuous infusion, and liposomal delivery of doxorubicin to tumor cells.

Authors:  A W El-Kareh; T W Secomb
Journal:  Neoplasia       Date:  2000 Jul-Aug       Impact factor: 5.715

2.  Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.

Authors:  Stephanie L Ham; Ramila Joshi; Gary D Luker; Hossein Tavana
Journal:  Adv Healthc Mater       Date:  2016-09-07       Impact factor: 9.933

3.  Quantitation of cell-associated doxorubicin by high-performance liquid chromatography after enzymatic desequestration.

Authors:  A Andersen; D J Warren; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Downregulation of mdr-1 expression by 8-Cl-cAMP in multidrug resistant MCF-7 human breast cancer cells.

Authors:  S Scala; A Budillon; Z Zhan; Y S Cho-Chung; J Jefferson; M Tsokos; S E Bates
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

5.  The Chemistry and Biology of Nakiterpiosin - C-nor-D-Homosteroids.

Authors:  Shuanhu Gao; Qiaoling Wang; Gelin Wang; Brett Lomenick; Jie Liu; Chih-Wei Fan; Lih-Wen Deng; Jing Huang; Lawrence Lum; Chuo Chen
Journal:  Synlett       Date:  2012-10       Impact factor: 2.454

6.  Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation.

Authors:  John P Sinek; Sandeep Sanga; Xiaoming Zheng; Hermann B Frieboes; Mauro Ferrari; Vittorio Cristini
Journal:  J Math Biol       Date:  2008-09-10       Impact factor: 2.259

7.  Antitumor activities of new platinum compounds, DWA2114R, NK121 and 254-S, against human leukemia cells sensitive or resistant to cisplatin.

Authors:  H Kobayashi; Y Takemura; H Miyachi; T Ogawa
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

8.  Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.

Authors:  H Kobayashi; Y Takemura; T Ohnuma
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

9.  Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.

Authors:  Y Takemura; W Gibson; R Kimbell; H Kobayashi; H Miyachi; A L Jackman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

10.  Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.

Authors:  Y Takemura; H Kobayashi; H Miyachi; W Gibson; R Kimbell; A L Jackman
Journal:  Jpn J Cancer Res       Date:  1996-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.